A phase I trial of the antiangiogenesis agent cilengitide (EMD 121974), an alpha v beta 3,5 integrin antagonist, was performed to estimate the maximum-tolerated dose (MTD) and describe dose-limiting toxicities (DLTs) and the incidence and severity of other toxicities when administered to children with refractory brain tumors.
INTRODUCTION
Angiogenesis, which is critical for tumor growth, is induced by tumor secretion of vascular growth factors that activate endothelial cell proliferation, survival, and maturation. 1 A consequence of this activation is expression on endothelial cells of integrin receptors, whose presence is crucial for continued endothelial cell survival. The ␣v␤3 and ␣v␤5 integrins are particularly important in angiogenesis and, therefore, represent logical targets for antiangiogenesis strategies to treat malignancies.
2-5 These integrins allow endothelial cells to attach to the extracellular matrix through their ability to bind to arginine-glycine-aspartic acid (RGD) amino acid sequences found on matrix proteins. 6, 7 Thus, one approach to inhibiting angiogenesis is to use RGDcontaining peptide antagonists. 8 Specificity for the ␣v␤3 and ␣v␤5 receptors can be significantly enhanced by cyclizing RGD peptides. Cilengitide (EMD121974; Merck KGaA, Darmstadt, Germany), the inner salt of a cyclized RGD pentapeptide (cyclo-[Arg-Gly-Asp-DPhe-(NMeVal)]), is a potent and selective ␣v␤3 and ␣v␤5 antagonist. [9] [10] [11] Cilengitide inhibits tumor growth in a dosedependent manner in a variety of in vivo systems including athymic mice inoculated intracerebrally with human medulloblastoma and glioblastoma cells. [12] [13] [14] [15] [16] [17] Several phase I and II trials conducted in adult patients with advanced solid tumors have used cilengitide as a 1-hour infusion twice weekly (dosages: 30 to 1,600 mg/m 2 /d).
18- 21 The most frequently recorded toxicities were nausea and fatigue. Other mild toxicities include rash, pruritus, and vomiting. In these trials, neither significant hematologic toxicity nor evidence of cumulative toxicity was observed JOURNAL OF CLINICAL ONCOLOGY after repeated cilengitide administration. The phase I and II New Approaches to Brain Tumor Therapy (NABTT) 9911 study was a dose-finding study (120 to 2,400 mg/m 2 ) for adults with recurrent malignant gliomas. Similar to the non-CNS studies, the majority of adverse events were mild to moderate, and a maximum-tolerated dose (MTD) was not reached. 21 Results of pharmacokinetic studies have shown an average cilengitide systemic clearance between 2.0 and 3.9 L/h/m 2 and a terminal half-life between 3 and 5 hours. 19 Cilengitide renal clearance ranged from 0.9 to 3.4 L/h/m 2 , accounting for most of the systemic clearance.
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On the basis of these studies, a phase I dose-escalation trial of cilengitide twice weekly as a 1-hour infusion was conducted for the treatment of children with refractory CNS tumors. The primary aims were to determine the optimal dosage and dose-limiting toxicities (DLTs) and to characterize the pharmacokinetics and pharmacogenomics of cilengitide in children. A secondary aim was to assess tumor response using serial magnetic resonance imaging (MRI).
PATIENTS AND METHODS

Patient Eligibility
Patients Յ 21 years of age with a primary CNS tumor that is recurrent or progressive and refractory to standard therapy, including benign CNS tumors (eg, low-grade glioma), were eligible. Karnofsky performance or Lansky score Ն 50, life expectancy of more than 8 weeks, and normal organ function were required.
The institutional review boards of each Pediatric Brain Tumor Consortium institution approved the protocol before initial patient enrollment, and continuing approval was maintained throughout the study. Patients or their legal guardians gave written informed consent, and assent was obtained as appropriate at the time of enrollment.
Restrictions included no investigational agent within 2 weeks; no nitrosourea or myelosuppressive therapy within 6 or 4 weeks, respectively; no bone marrow transplantation within 6 months; no radiation therapy within 6 weeks; no craniospinal irradiation (Ͼ 24 Gy) or total-body irradiation within 3 months; and no local palliative irradiation within 2 weeks before study entry. Patients could not be receiving any other anticancer or experimental drug therapy, with the exception of corticosteroids.
Statistical Methods
A modified continual reassessment method (CRM) 22,23 was used to assign dosage levels and to estimate the MTD, which is defined as the dosage at which 25% of patients are expected to experience a DLT during the first course of treatment. The initial dosage assigned was 120 mg/m 2 , and the trial was to continue until at least six assessable patients had been treated and observed for toxicity at the dose-finding MTD, which is the prespecified dosage level closest to the CRM-estimated MTD. Once the MTD was established, additional accrual to that dosage level was permitted until a total of 12 patients had been enrolled to gain additional experience with the toxicity of cilengitide.
The CRM model was continually updated, and dosage escalation decisions were made as toxicity information became known for each patient. Subsequent dosage levels were determined to be the prespecified level closest to the CRM-estimated MTD without skipping a level that had been assigned to fewer than two assessable patients.
The cumulative incidence functions of intratumoral hemorrhage (ITH), as measured from date on therapy to the earliest date of a competing event (disease progression or death), diagnosis of ITH, or last contact, were estimated by methods discussed in Kalbfleish and Prentice.
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Study Design
Cilengitide was supplied by the Division of Cancer Treatment and Diagnosis of the National Cancer Institute, provided under a Cooperative Research and Development Agreement between EMD Pharmaceuticals Inc (Durham, NC) and Merck KGaA. Cilengitide was administered by intravenous infusion over 1 hour twice weekly, with at least 2 days between doses and no interruptions of this schedule. Each 4-week period was defined as a course, and a total of 13 courses (1 year) could be administered in the absence of unacceptable toxicity or tumor progression.
Cilengitide dosing was started at 120 mg/m 2 , the starting dosage used in the NABTT trial. Dose escalations proceeded in subsequent patient cohorts until the MTD or the final dosage of 2,400 mg/m 2 was reached (Table 1) . Toxicities observed during the first 4 weeks of therapy were assessed to guide dose escalation. No intrapatient dosage escalation was allowed; however, deescalation to the next lowest dosage level was permitted for specifically defined toxicities that occurred beyond the first 4 weeks of therapy. All patients were considered to have concluded protocol therapy at the completion of 1 year of treatment. Abbreviation: NOS, not otherwise specified. *Two patients were not assessable for maximum-tolerated dose estimation.
Toxicities were graded according to the National Cancer Institute Common Toxicity Criteria (version 2.0), and DLT was defined as any grade 3 or 4 nonhematologic toxicity (with the exclusion of grade 3 nausea and vomiting controlled with antiemetics and grade 3 transaminase [AST/ALT] elevation that returns to Յ grade 1 within 7 days of stopping the drug), grade 3 or 4 thrombocytopenia, or grade 4 neutropenia that was considered at least possibly related to the investigational agent and occurring during the initial 4 weeks of therapy, regardless of expectedness.
Patient Evaluation
Standard MRI scans were obtained to measure disease response. The imaging studies were analyzed by the Pediatric Brain Tumor Consortium Neuroimaging Center. Studies were conducted before therapy (within 4 weeks before the initiation of therapy), after the first 8 weeks of therapy (after course 2), and every 12 weeks thereafter. Spinal MRI was performed before therapy and repeated only if initially positive or if clinically indicated. Responses were defined as complete response (CR) if there was complete disappearance on MRI of all enhancing tumor and mass effect maintained for at least 6 weeks; also, if CSF was positive, it must become negative. Partial response (PR) was defined as Ն 50% reduction in tumor size maintained for at least 6 weeks. Stable disease (SD) was determined if the MRI met neither the criteria for PR nor progressive disease and this was maintained for a clinically appropriate interval (eg, 12 weeks for malignant gliomas) to be deemed of clinical benefit. To be declared CR, PR, or SD, responses needed to be accompanied by a stable or improving neurologic examination on a stable or decreasing dose of corticosteroids. Progressive disease was defined as worsening neurologic status related to tumor progression or a greater than 25% increase in tumor size; the presence of new tumor on MRI; or increasing doses of corticosteroids required to maintain stable neurologic status or imaging. Because cilengitide is a cytostatic agent, it was felt that there might be a lag time between the initiation of therapy and antitumor effect; therefore, patients were allowed to remain on therapy until the tumor had increased at least 50% in size from baseline provided no significant clinical symptoms were observed from tumor enlargement. In the latter case, the patient was considered to have progressive disease and was taken off therapy.
Pharmacokinetic Studies
Serial plasma samples (2 mL) for pharmacokinetic studies were collected in heparinized tubes with the first dose of courses 1 and 2 at the following times: before dose; at the end of infusion; and at hours 0.5, 1, 1.5, 2, 4, 6, and 24. A 24-hour urine collection for cilengitide was performed with the first dose of course 1. Two CSF samples were obtained from one patient with an indwelling Ommaya reservoir. Plasma, urine, and CSF samples were processed, and cilengitide concentrations were analyzed by an isocratic liquid chromatography/mass spectrometry/mass spectrometry method. 25 The lower limit of quantitation of cilengitide was 20 ng/mL, and the within-run and between-run coefficient of variation was less than 5%.
A two-compartment model was fitted to the cilengitide plasma concentrations using maximum likelihood estimation as implemented in ADAPT II. 26 Parameters estimated included volume of the central compartment, elimination rate constant, and intercompartment rate constants. Systemic clearance, renal clearance, and beta half-life were calculated by standard equations, and the area under the concentration-time curve (AUC) from zero to 24 hours for cilengitide was calculated by integration of the simulated concentrationtime data from model estimates.
Pharmacogenetic Studies
In consenting patients, whole blood was collected before treatment with cilengitide. Genomic DNA was extracted using standard molecular procedures, and 10 ng of DNA from each patient was used for genotyping. ABCB1 polymorphisms in exon 21 (G2677T/A) and exon 26 (C3435T) were genotyped by polymerase chain reaction (PCR) amplification followed by sequencing.
27 ABCG2 polymorphisms in exon 2 (G34A) and exon 5 (C421A) were genotyped as described 28 with the following modifications: 10 ng of genomic DNA was used as template, and annealing for the exon 2 and 5 PCR reactions was at 55°C. For all polymorphisms, amplification product (4 L) was sequenced using the forward PCR primer.
RESULTS
Patient Characteristics
Between July 2003 and March 2005, 35 patients were enrolled onto the trial, of whom 33 started receiving the study drug and 31 were deemed assessable for toxicity over seven dosage levels ranging from 120 to 2,400 mg/m 2 ( Table 1 ). The study was completed in January 2006.
Toxicity
No DLTs were observed, and thus, the MTD of cilengitide was not estimated. Table 2 lists the toxicities that were deemed at least possibly related to study drug. Three of 13 patients (two with glioblastoma multiforme [GBM] and one with brainstem glioma) at the dosage level of 2,400 mg/m 2 experienced grade 3 or 4 ITH possibly related to the study drug. However, two of the ITH events were asymptomatic, which, by the current Common Terminology Criteria of Adverse Events (version 3), would be classified as grade 1. ITH occurred at 44, 57, and 139 days after initiation of the protocol therapy; all ITHs occurred after the DLT observation period and, therefore, were not DLTs. The 6-month cumulative incidence estimate of ITH is 12.1% (SE ϭ 6%; Appendix Fig A1, online only) . For patients treated at 2,400 mg/m 2 of cilengitide, the 6-month cumulative incidence estimate of ITH is 23% (SE ϭ 13%). The dose was subsequently reduced to 1,800 mg/m 2 for all remaining patients. One patient at 480 mg/m 2 had ITH unrelated to the study drug. No ITH was observed at 1,800 mg/m 2 . 
‫ء‬
If a patient has the same toxicity more than once during treatment, then the maximum toxicity has been shown. †Observed during the dose-limiting toxicity observation period.
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Antitumor Activity
The best response demonstrated was one CR at 1,200 mg/m 2 in a patient with recurrent GBM. This patient completed the 1-year protocol therapy and had sustained CR for more than 1 year with clinical improvement in symptoms. Three patients had SD for at least 22 weeks, including two patients who completed a year of protocol therapy. An additional three patients had stable neurologic examinations after the first two courses of treatment (8 weeks) and SD documented by the initial MRI but did not meet the criteria defined by the protocol for declaring SD of clinical benefit. The patients with documented SD by the initial response MRI include the following: one at 480 mg/m 2 (medulloblastoma, SD for 8.4 weeks), one at 720 mg/m 2 (fibrillary astrocytoma, SD for 8.4 weeks), and four at 2,400 mg/m 2 (GBM, SD for 6.9 weeks; ependymoma, SD for 22.6 weeks; ependymoma, SD for 52 weeks; and optic pathway glioma, SD for 52.4 weeks; Table 3 ).
Pharmacokinetics
Pharmacokinetic studies were collected on 22 consenting patients, but only 19 were assessable for pharmacokinetic modeling (eg, venous access problems, and so on). A representative cilengitide plasma concentration-time plot is shown in Figure 1 . The median cilengitide plasma beta half-life and systemic clearance were 4.6 hours (range, 1.9 to 17.9 hours) and 4.7 L/h/m 2 (range, 2.3 to 9.3 L/h/m 2 ), respectively. The cilengitide renal clearance was determined in 10 patients, and the median was 2.9 L/h/m 2 (range, 0.4 to 9.3 L/h/m 2 ). The cilengitide AUC from zero to 24 hours and maximum concentration increased with dosage over the dosage range studied (Figs 2A and 2B) . Using a compartmental modeling approach, we estimated that the cilengitide CSF penetration (AUC CSF to ACU plasma ) was 1.2% for the patient with the indwelling Ommaya reservoir.
Lastly, we used the data from these 19 patients to create a limited sampling model for use in further clinical trials of cilengitide. To determine the optimal sampling times, we used a variation of D-optimality, which included the earlier described pharmacokinetic data. We also constrained the sampling scheme to three samples before 8 hours because of logistical considerations. This procedure produced the sampling method of 1, 3, and 6 hours after the end of the infusion. We tested the optimal sampling scheme along with several variations in our set of 19 patients. In all cases, the parameter estimates for the limited sampling model were obtained using maximum a posteriori probability estimator (ADAPT II). Accuracy was measured relative to the pharmacokinetic parameters determined using all plasma samples and showed that, for cilengitide, median clearance accuracy was 6% (range, 2% to 14%).
Pharmacogenetics
Of the 35 patients on study, 11 patients denied participation in pharmacogenetic studies, two patients had inadequate DNA for genotyping studies, and one patient was declared ineligible for the clinical trial. Genotyping studies were performed for two polymorphisms in ABCB1 and ABCG2 in the remaining 21 patients (the results for the ABCB1 exon 26 genotype were inconclusive on one patient), and we observed the following: ABCG2 exon 2 (G34A) G/A (n ϭ 1) and G/G (n ϭ 21); ABCG2 exon 5 (C421A) C/A (n ϭ 1) and C/C (n ϭ 21); ABCB1 exon 21 (G2677T) G/G (n ϭ 11) and G/T (n ϭ 9), T/T (n ϭ 2); and ABCB1 exon 26 C3435T C/C (n ϭ 4), C/T (n ϭ 15), and T/T (n ϭ 2). Of the 15 patients with adequate DNA and results from the cilengitide pharmacokinetic studies, we noted a relationship between cilengitide systemic and renal clearance and ABCB1 genotype, as depicted in Figure 3 .
DISCUSSION
This is the first report of cilengitide administration in children. In this study restricted to pediatric patients with refractory brain tumors, no DLTs were observed, and thus, an MTD was not estimated. However, three serious adverse events of ITH were noted (two grade 3 and one grade 4), which were possibly related to the study drug. These adverse events occurred at the dosage level of 2,400 mg/m 2 after the DLT observation period. The two grade 3 events were asymptomatic and would be considered grade 1 by the current Common Terminology Criteria of Adverse Events (version 3) criteria. The remaining patient had ITH in the setting of tumor progression. All patients who were receiving 2,400 mg/m 2 of cilengitide at the time of the serious adverse events had their doses reduced to 1,800 mg/m 2 . No hemorrhages were observed in three patients receiving 1,800 mg/m 2 and in the remaining nine patients who received 2,400 mg/m 2 . Therefore, it is concluded from this study that 1,800 mg/m 2 is a safe dose in pediatric brain tumor patients without increased risk or overt evidence of ITH.
To date, only one other study of cilengitide administration in patients with CNS tumors has been published, the NABTT-9911 study, a phase I/II trial of cilengitide for the treatment of recurrent malignant glioma in adults. In the NABTT study, which enrolled 51 patients over a dosage range identical to our study, no ITH was reported, an MTD was not estimated, and the majority of toxicities were mild to moderate. However, four DLTs were recorded (grade 3 thrombosis, grade 4 myalgia and arthralgia, and grade 3 thrombocytopenia), and one patient experienced grade 3 anorexia, hyperglycemia, hypokalemia, and hyponatremia. 21 Cilengitide systemic and renal clearances in our pediatric population were similar to those observed in adults; however, we observed more interpatient variability. 21 With the exception of two patients (half-lives of 14 and 17.9 hours), the terminal half-life values observed in our patient population were similar to those found in adult studies. 21 Although characterized by wide interpatient variability, the cilengitide plasma concentrations increased as the cilengitide dosage increased. Patients treated at all dosage levels greater than 120 mg/m 2 achieved plasma concentrations associated with growth inhibition in animal models. 19 In the event that further cilengitide pharmacokinetic studies in phase II clinical trials are proposed or cilengitide dosage individualization is proposed, we developed and validated a limited sampling model for cilengitide. This model uses three sample time points to calculate cilengitide pharmacokinetic parameters accurately and without bias.
Unpublished reports have suggested that cilengitide is a substrate for several ABC transporters, including ABCB1 or P-glycoprotein. 18 This polymorphic efflux transport protein is present in many tissues in the body, including the brain, gut, liver, and kidney, and as such is responsible for the disposition of many compounds. However, an inconsistent relationship between ABCB1 genotype and pharmacokinetic phenotype has been reported for most drugs. 29 In our small patient population studied for pharmacogenomics, we noted a suggestive relationship between ABCB1 genotype, specifically exon 26 C to T, and cilengitide systemic and renal clearance. It will be important to continue to study this relationship in larger patient populations. This will be especially true if a relationship between cilengitide plasma concentrations and effect (toxicity or efficacy) are noted because patients with the TT polymorphism could have an increased exposure to cilengitide.
Finally, the responses demonstrated in our study are encouraging for preliminary evidence of activity of this agent against pediatric brain tumors. Similarly, five patients enrolled onto the NABTT-9911 study had an objective response to therapy, including two CRs and three PRs, and 16 patients experienced SD. 21 Given our results, we conclude that phase II testing of cilengitide should be initiated for children with refractory brain tumors. 
